Reid Laurence
SEC insider (Form 3/4/5 filer). CIK 0001492749. Director at Metagenomi Therapeutics, Inc. (MGX) and 1 other issuer. 6 reported Form 4/5 transactions since Sep 2024; latest on Sep 9, 2026. Located in EMERYVILLE, CA.
Companies Reid Laurence has filed insider reports for
- Metagenomi Therapeutics, Inc. (MGX): Director
- KalVista Pharmaceuticals, Inc. (KALV): Director
Reid Laurence
CIK: 0001492749
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (6 total)
- Sep 9, 2026MGX
Metagenomi Therapeutics, Inc.
PurchaseDirect19.9K shares at avg. $1.17$23K - Sep 9, 2026MGX
Metagenomi Therapeutics, Inc.
PurchaseDirect117 shares at avg. $1.18$138.06 - Jun 11, 2026KALV
KalVista Pharmaceuticals, Inc.
DispositionDirectStock Option (Right to Buy)
17K shares- - Jun 9, 2026MGX
Metagenomi Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
17.4K shares- - Sep 2, 2025MGX
Metagenomi, Inc.
AwardDirectStock Option (Right to Buy)
42K shares- - Nov 23, 2024KALV
KalVista Pharmaceuticals, Inc.
AwardDirectStock Option (Right to Buy)
17K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Sep 9, 2026 |  MGX Metagenomi Therapeutics, Inc. | Purchase | 19,883 | $1.17 | $23,263 | Direct |
| Sep 9, 2026 | MGX Metagenomi Therapeutics, Inc. | Purchase | 117 | $1.18 | $138 | Direct |
| Jun 11, 2026 |  KALV KalVista Pharmaceuticals, Inc. | Disposition Stock Option (Right to Buy) | 17,000 | - | - | Direct |
| Jun 9, 2026 | MGX Metagenomi Therapeutics, Inc. | Award Stock Option (Right to Buy) | 17,400 | - | - | Direct |
| Sep 2, 2025 | MGX Metagenomi, Inc. | Award Stock Option (Right to Buy) | 42,000 | - | - | Direct |
| Nov 23, 2024 | KALV KalVista Pharmaceuticals, Inc. | Award Stock Option (Right to Buy) | 17,000 | - | - | Direct |
1-6 of 6 transactions